Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 557 • 2015 ACR/ARHP Annual Meeting
Early Intensification of Treatment Induces Superior Outcomes in Two Randomized Trials According to Predicted Vs. Observed Radiographic Progression in Rheumatoid Arthritis
Adrian Levitsky¹, Marius C. Wick², Timo Möttönen³, Marjatta Leirisalo-Repo⁴, Leena Laasonen⁵, Hannu Kautiainen^6,7, Markku Korpela⁸, Ronald F. van Vollenhoven¹ and Vappu Rantalaiho⁸, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Radiology, Karolinska University Hospital, Stockholm, Sweden, ³Internal Medicine, Division of Rheumatology, Turku University Central Hospital, Turku, Finland, ⁴Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁵Helsinki Medical Imaging Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁶Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁷Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, ⁸Department of Internal Medicine, Center for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland
Background/Purpose: Predicted vs. Observed Radiographic Progression in early Rheumatoid Arthritis (POPeRA) is a method that has previously confirmed the relative radiographic efficacy of synthetic disease-modifying…
Abstract Number: 2129 • 2015 ACR/ARHP Annual Meeting
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Abnormalities of Vascular and Myocardial Function on Cardiac MRI
Bara Erhayiem¹, Adam McDiarmid¹, Peter Swoboda¹, Ananth Kidambi¹, David Ripley¹, Tarique Musa¹, Laura Dobson¹, Pankaj Garg¹, Sarah Horton², Raluca Dumitru³, Jacqueline Andrews⁴, John Greenwood⁵, Paul Emery^4,6, Sven Plein¹ and Maya H. Buch^2,7, ¹Leeds Institute of Cardiovascular And Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Cardiovascular And Metabolic Medicinee, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷NIHR - Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom
Treatment-na•ve, early rheumatoid arthritis patients demonstrate abnormalities of vascular and myocardial function on cardiac MRIB Erhayiem, A McDiarmid, PP Swoboda, A Kidambi, DP Ripley, TA…
Abstract Number: 434 • 2015 ACR/ARHP Annual Meeting
Duration of Remission By Currently Available Criteria Can Predict Physical Functioning, but Not Radiological Progression in Early Rheumatoid Arthritis Patients
Nicole P.C. Konijn¹, Lilian H.D. van Tuyl¹, Maarten Boers^1,2, D den Uyl¹, M.M. ter Wee¹, P.J.S.M. Kerstens^3,4, Alexandre E. Voskuyl⁵, Michael T. Nurmohamed^1,3, Dirkjan van Schaardenburg^3,6 and Willem F. Lems^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ²Epidemiology & Biostatistics, VU University medical center, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ⁴Rheumatology, Westfriesgasthuis, Hoorn, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, ⁶Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Several sets of remission criteria have been developed. The ACR/EULAR criteria were validated against their potential to predict prognosis of rheumatoid arthritis (RA) [1].…
Abstract Number: 568 • 2015 ACR/ARHP Annual Meeting
Superiority of Initial Combination- over Step up Therapy in Treatment to the Target of Remission in Daily Clinical Practice in Early Rheumatoid Arthritis Patients: Results from the DREAM Registry
Laura M.M. Steunebrink¹, G.A. Versteeg¹, Harald E. Vonkeman², Peter M. ten Klooster³, Ina H. Kuper¹, Arie E. van der Bijl⁴, Piet L.C.M. van Riel⁵ and Mart A.F.J. van de Laar¹, ¹Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Pcgr, University of Twente, Enschede, Netherlands, ⁴Isala Klinieken, Zwolle, Netherlands, ⁵Rheumatology, Bernhoven, Uden, Netherlands
Background/Purpose: Treat-to-target (T2T) of remission strategies has been widely accepted as the standard of care for patients with Rheumatoid Arthritis (RA). In early RA, implementation…
Abstract Number: 2595 • 2015 ACR/ARHP Annual Meeting
Autoantibodies to Citrullinated Fibrinogen, Anti-CCP2 and Anti-MCV Antibodies in Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression at 1-Year
Yannick Degboé¹, Arnaud Constantin², Delphine Nigon³, Gabriel Tobon⁴, Martin Cornillet⁵, Thierry Schaeverbeke⁶, Gilles Chiocchia⁷, Pascale Nicaise-Roland⁸, Leonor Nogueira⁹, Guy Serre^5,10,11, Alain G. Cantagrel¹² and Adeline Ruyssen Witrand^13,14, ¹Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France, ²Inserm U558, Rheumatology Center, Purpan University Hospital, Toulouse, France, ³CHU Purpan, Toulouse, France, ⁴Rheumatology Department, la Cavale Blanche Hospital, Brest, France, ⁵Service de Biologie Cellulaire, C.H.U. Purpan, Toulouse, France, ⁶CHU Bordeaux, Bordeaux, France, ⁷Immunology-Rheumatology, INSERM U1173, paris, France, ⁸Immunology Department, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France, ⁹Immunology, UMR CNRS 5165, INSERM 1056, Toulouse, France, ¹⁰Cell Biology, Purpan University Hospital, Toulouse, France, ¹¹Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM,Toulouse, France, Toulouse, France, ¹²Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ¹³Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ¹⁴UMR 1027, Inserm, Toulouse, France
Background/Purpose: We compared the ability of anti-CCP2, anti-mutated citrullinated vimentin (anti-MCV) and anti-citrullinated fibrinogen (AhFibA) antibodies to predict 1-year rapid radiographic progression (RRP; total Sharp…
Abstract Number: 454 • 2015 ACR/ARHP Annual Meeting
No Sex Bias in the Escalation of Therapy in the Treatment of Early Inflammatory Arthritis
Stephanie Garner¹, Cheryl Barnabe², Gilles Boire³, Carol Hitchon⁴, Edward C. Keystone⁵, Boulos Haraoui⁶, J Carter Thorne⁷, Diane Tin⁸, Janet E. Pope⁹, VP Bykerk¹⁰ and CATCH Investigators, ¹University of Calgary, Calgary, AB, Canada, ²Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁵Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Institut de Rhumatologie, Montreal, QC, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹University of Western Ontario, London, ON, Canada, ¹⁰Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Several studies have shown that females with early inflammatory arthritis have higher disease activity, worse functional impairment and worse patient-reported outcomes but do not…
Abstract Number: 571 • 2015 ACR/ARHP Annual Meeting
Malignancy Data in Tofacitinib-Treated Japanese Patients with Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisashi Yamanaka³, Naonobu Sugiyama M.D., Ph.D⁴, Takunari Yoshinaga⁴, Kanae Togo⁴, Jamie Geier⁵, Mary Boy⁵ and Carol Connell⁵, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Tokyo Women’s Medical University, Tokyo, Japan, ⁴Pfizer Japan Inc, Tokyo, Japan, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In the global tofacitinib RA clinical program, rates and types…
Abstract Number: 2620 • 2015 ACR/ARHP Annual Meeting
Predictive Value of Anti-Carbamylated Protein Antibodies in Patients with Early Arthritis
Cristina Regueiro¹, Diana Peiteado², Laura Nuño³, Alejandro Villalba⁴, Dora Pascual-Salcedo⁵, Ana Martínez⁶, Alejandro Balsa⁴ and Antonio Gonzalez⁷, ¹Instituto Investigacion Sanitaria - Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ³Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁵Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ⁶Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁷Instituto Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
Background/Purpose: Anti-carbamylated protein (anti-CarP) antibodies have been described as a new type of autoantibodies specific of patients with rheumatoid arthritis (RA). They seem useful as…
Abstract Number: 466 • 2015 ACR/ARHP Annual Meeting
Clinical Factors, Anti-Citrullinated Peptide Antibodies and MRI-Detected Subclinical Inflammation in Relation to Progression from Clinically Suspect Arthralgia to Arthritis
H.W. van Steenbergen¹, L. Mangnus², M. Reijnierse³, T. W. J. Huizinga¹ and A.H.M. van der Helm- van Mil², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Radiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients with Clinically Suspect Arthralgia (CSA) have, according to their rheumatologists, an increased risk on rheumatoid arthritis (RA), but their actual outcome is unexplored.…
Abstract Number: 596 • 2015 ACR/ARHP Annual Meeting
Long-Term High Remission Rates and Distinct Trajectories of Disease Activity Following the Implementation of Treat-to-Target in Early Rheumatoid Arthritis
Letty G.A. Versteeg¹, Laura M.M. Steunebrink¹, Ina H. Kuper¹, Peter M. ten Klooster², Arie E. van der Bijl³, Harald E. Vonkeman⁴ and Mart A.F.J. van de Laar¹, ¹Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²Pcgr, University of Twente, Enschede, Netherlands, ³Isala Klinieken, Zwolle, Netherlands, ⁴Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands
Background/Purpose: Treat-to-target (T2T) in early Rheumatoid Arthritis (RA) has been successfully implemented in daily clinical practice. Patients achieve remission very early and during a follow-up…
Abstract Number: 2648 • 2015 ACR/ARHP Annual Meeting
Vitality, Presenteeism, and Their Determinants in Patients with Early Rheumatoid Arthritis Treated with a 6-Month Induction Infliximab Therapy Added on a Triple Combination Therapy
Vappu Rantalaiho¹, Marjatta Leirisalo-Repo², Hannu Kautiainen³, Petri Mankinen⁴, Janne Martikainen⁵ and Kari Puolakka⁶, ¹Department of Internal Medicine, Center for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland, ²Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ³Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁴Pharmacoeconomics & Outcomes Research Unit (PHORU), School of Pharmacy, University of Eastern Finland, Kuopio, Finland, ⁵Pharmacoeconomics and Outcomes Research Unit, School of Pharmacy, University of Eastern Finland, Kuopio, Finland, ⁶Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland
Background/Purpose: To evaluate vitality, reduced paid and unpaid work ability, and productivity losses for patients with early rheumatoid arthritis (RA) available for work force at…
Abstract Number: 468 • 2015 ACR/ARHP Annual Meeting
Clinical and Ultrasonographic Inflammation in DMARD-Naïve Early Rheumatoid Arthritis (RA) – Impact of the 2010 ACR/EULAR Classification Criteria Versus the 1987 ACR Classification Criteria
Maria K. Jonsson^1,2,3, Siri Lillegraven², Lena B. Nordberg², Anna-Birgitte Aga², Hilde B. Hammer⁴, Inge C Olsen², Bjørg-Tilde Fevang^1,5, Tore K. Kvien², Espen A. Haavardsholm² and the ARCTIC Study Group, ¹Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Clinical Science, University of Bergen, Bergen, Norway, ⁴Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: ACR and EULAR published new classification criteria for RA in 2010, aiming for early identification of patients at risk of developing persistent and erosive…
Abstract Number: 609 • 2015 ACR/ARHP Annual Meeting
A Reduction in Serum Uric Acid Levels May be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from a Canadian Arthritis Cohort
Jason Lee¹, VP Bykerk², George Dresser³, Gilles Boire⁴, Boulos Haraoui⁵, Carol Hitchon⁶, J Carter Thorne², Diane Tin⁷, Shahin Jamal⁸, Edward C. Keystone⁹, Janet E. Pope¹⁰ and CATCH Investigators, ¹Rheumatology, Western University, St. Joseph's Hospital, London, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Clinical Pharmacology and Toxicology, Western University, London, ON, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Institut de Rhumatologie, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Vancouver Coastal Health, Vancouver, BC, Canada, ⁹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada
Background/Purpose: The mechanism of methotrexate in rheumatoid arthritis (RA) is complex. It may increase adenosine levels by blocking conversion to of xanthine to uric acid…
Abstract Number: 2655 • 2015 ACR/ARHP Annual Meeting
Clinically Important Worsening (CIW) of RA Disease Activity Requiring an Increase in Therapy Can be Identified Using a Combined Patient and Physician Report of Flare
VP Bykerk^1,2, Clifton O. Bingham III³, Ernest H. Choy⁴, Daming Lin², Rieke Alten⁵, Robin Christensen⁶, Daniel E. Furst⁷, Francis Guillemin⁸, Sarah Hewlett⁹, Amye L. Leong¹⁰, Lyn March¹¹, Thasia Woodworth¹², Gilles Boire¹³, Carol Hitchon¹⁴, Shahin Jamal¹⁵, Edward C. Keystone¹⁶, Janet E. Pope¹⁷, J Carter Thorne¹⁸, Diane Tin¹⁹, Susan J. Bartlett^20,21,22 and CATCH Investigators and OMERACT Flare Group, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ⁵Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁶The Parker instutute, RC, Copenhagen, Denmark, ⁷Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸University of Lorraine, Nancy, France, ⁹Academic Rheumatology, University of West of England, Bristol, United Kingdom, ¹⁰Spokesperson; Strategic Relations, BONE AND JOINT DECADE, Santa Barbara, CA, ¹¹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹²Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, ¹³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ¹⁴Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada, ¹⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁷Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada, ¹⁸University of Toronto, Toronto, ON, Canada, ¹⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ²⁰Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²²Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: A reference point for clinically important worsening (CIW) of RA disease activity requiring retreatment or escalation is needed for randomized trials of treatment withdrawal.…
Abstract Number: 470 • 2015 ACR/ARHP Annual Meeting
Disease Outcome in Patients Fulfilling the 2010 Classification Criteria for Rheumatoid Arthritis: The Impact of the Different Criteria Components
Ellen Sauar Norli^1,2, Gina Hetland Brinkmann^2,3, Tore K. Kvien², Olav Bjørneboe¹, Anne Julsrud Haugen³, Halvor Nygaard⁴, Cathrine Thunem⁵, Elisabeth Lie² and Maria Dahl Mjaavatten², ¹Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Østfold Hospital Trust, Fredrikstad, Norway, ⁴Dept. of Rheumatology, Lillehammer Hospital of Rheumatic Diseases, Lillehammer, Norway, ⁵Dept. of Rheumatology, Betanien Hospital, Skien, Norway
Background/Purpose: The 2010 ACR/EULAR classification criteria for rheumatoid arthritis (2010 RA criteria) facilitate early classification of rheumatoid arthritis (RA). The criteria yield a score ranging…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].